title: [Mitral valvuloplasty for asymptomatic or pauci-symptomatic mitral insufficiency].
abstract: The aim of this study was to assess the results of mitral valvuloplasty for chronic asymptomatic or paucisymptomatic mitral regurgitation. Of 584 patients operated for chronic mitral regurgitation between January 1989 and December 1994, 175 were in NYHA Classes I and II and made up the study population. All had chronic grade 3 or 4/4 mitral regurgitation suitable for mitral valvuloplasty. The average follow-up was 34.3 months. Mitral valvuloplasty was performed in 174 patients, the other patient requiring mitral valve replacement. Three patients died (1.7%) and the actuarial 5 year survival was 98.2 +/- 1.0%. The probability of absence of reoperation and absence of thrombo-embolic complications at 5 years were 97 +/- 0.8% and 96.3 +/- 1.7% respectively. The residual regurgitation at Doppler echocardiography was minimal or absent in 94% of patients at the last follow-up control. The mean end-systolic and end-diastolic left ventricular dimensions decreased from 40.0 +/- 6.8 mm and 64.8 +/- 7.0 mm before surgery to 34.6 +/- 6.7 mm (p < 0.001) and 52.7 +/- 7.4 mm (p < 0.001) at the last control. The authors conclude that conservative mitral valve surgery for NYHA Classes I and II patients with chronic mitral regurgitation is feasible with a low risk and is associated with a significant reduction in ventricular volumes and stability of valvular continence at medium-term. When performed by teams trained in techniques of mitral valvuloplasty, these results suggest that surgery should be performed early.
authors.affiliation: Service de chirurgie cardiaque, Hôpital Européen de Paris La Roseraie, Aubervilliers.
authors.forename: M
authors.initials: M
authors.lastname: Sousa Uva
authors.forename: G
authors.initials: G
authors.lastname: Dreyfus
authors.forename: G
authors.initials: G
authors.lastname: Rescigno
authors.forename: N
authors.initials: N
authors.lastname: al Aile
authors.forename: R
authors.initials: R
authors.lastname: Mascagni
authors.forename: F
authors.initials: F
authors.lastname: Pouillart
authors.forename: R
authors.initials: R
authors.lastname: Raffoul
authors.forename: M
authors.initials: M
authors.lastname: Scorsin
authors.forename: J P
authors.initials: JP
authors.lastname: Saal
authors.forename: A
authors.initials: A
authors.lastname: Lessana
mesh_terms: D000206:Actuarial Analysis; D000368:Aged; D001281:Atrial Fibrillation / Q000150:complications / Q000601:surgery / Q000628:therapy; D002306:Cardiac Volume; D002404:Catheterization / Q000009:adverse effects; D002423:Cause of Death; D002908:Chronic Disease; D015150:Echocardiography, Doppler; D005240:Feasibility Studies; D005260:Female; D005500:Follow-Up Studies; D019918:Heart Valve Prosthesis Implantation / Q000009:adverse effects; D006352:Heart Ventricles / Q000000981:diagnostic imaging; D006801:Humans; D008297:Male; D008875:Middle Aged; D008943:Mitral Valve / Q000000981:diagnostic imaging / Q000473:pathology* / Q000601:surgery; D008944:Mitral Valve Insufficiency / Q000145:classification / Q000000981:diagnostic imaging / Q000601:surgery / Q000628:therapy*; D012086:Reoperation; D012189:Retrospective Studies; D012307:Risk Factors; D015996:Survival Rate; D013923:Thromboembolism / Q000209:etiology; D016896:Treatment Outcome